Pfizer Inc. (NYSE: PFE) is scheduled to release its second-quarter financial results before the markets open on Tuesday. The consensus estimates from Thomson Reuters call for $0.74 in earnings per share (EPS) and $13.31 billion in revenue. The same period of last year reportedly had EPS of $0.67 and revenue of $12.9 billion.
Earlier this summer, the company announced that it would be committing over half a billion dollars to its venture capital arm. Essentially the firm intends to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle.
Additionally, Pfizer will extend its leadership as a venture capital investor with an expanded team that leverages expertise across venture capital investing, business development, drug discovery and clinical development.
As for the plan, Pfizer Ventures will seek to invest roughly 25% of its available capital ($150 million) in promising early-stage neuroscience companies. Ultimately Pfizer will be able to support a broad array of early neuroscience research and product development opportunities, which are critical in this nascent area of science.
Over the past 52 weeks, Pfizer has outperformed the broad markets with its stock up about 16%. In just 2018 alone, the stock is up only 6%.
A few analysts weighed in on Pfizer ahead of the report:
- BMO Capital Markets has a Buy rating and a $42 price target.
- Cantor Fitzgerald has a Buy rating with a $45 price target.
- Jefferies has a Hold rating with a $39 price target.
- Credit Suisse has a Neutral rating with a $39 target.
- Morgan Stanley has a Buy rating and a $43 target price.
- Societe General has a Neutral rating with a $39 target.
Shares of Pfizer were last seen at $38.61, with a consensus analyst price target of $39.80 and a 52-week trading range of $32.32 to $39.43.